Search Results

You are looking at 51 - 60 of 250 items for :

  • "Acute myeloid leukemia" x
  • Refine by Access: All x
Clear All
Full access

Myelodysplastic Syndromes

Peter L. Greenberg, Eyal Attar, John M. Bennett, Clara D. Bloomfield, Uma Borate, Carlos M. De Castro, H. Joachim Deeg, Olga Frankfurt, Karin Gaensler, Guillermo Garcia-Manero, Steven D. Gore, David Head, Rami Komrokji, Lori J. Maness, Michael Millenson, Margaret R. O’Donnell, Paul J. Shami, Brady L. Stein, Richard M. Stone, James E. Thompson, Peter Westervelt, Benton Wheeler, Dorothy A. Shead, and Maoko Naganuma

acute myeloid leukemia (AML). In the general population, the incidence rate of MDS is approximately 5 per 100,000 people per year. 1 , 2 MDS is rare among children/adolescents and young adults, with an incidence rate of 0.2 per 100,000 people per year

Full access

Sorafenib in Relapsed AML With FMS-Like Receptor Tyrosine Kinase-3 Internal Tandem Duplication Mutation

Smith Giri, Shadi Hamdeh, Vijaya Raj Bhatt, and James K. Schwarz

the potential benefits of the use of several therapies to treat patients with FLT3 -ITD mutations Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults, with an estimated incidence of 3 cases per 100,000 people. 1

Full access

Outcomes and Predictors of 28-Day Mortality in Patients With Hematologic Malignancies and Septic Shock Defined by Sepsis-3 Criteria

Nirmala K. Manjappachar, John A. Cuenca, Claudia M. Ramírez, Mike Hernandez, Peyton Martin, Maria P. Reyes, Alba J. Heatter, Cristina Gutierrez, Nisha Rathi, Charles L. Sprung, Kristen J. Price, and Joseph L. Nates

stem cell transplant type, and (D) severe neutropenia status (absolute neutrophil count <500/mm 3 ). Differences between the curves were assessed using the log-rank test. Abbreviations: ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia

Full access

Incorporating Tumor Characteristics to Maximize 21-Gene Assay Utility: A Cost-Effectiveness Analysis

Shi-Yi Wang, Tiange Chen, Weixiong Dang, Sarah S. Mougalian, Suzanne B. Evans, and Cary P. Gross

schematic view of the Markov model is summarized in Figure 2 . Patients entered the model in the recurrence-free state and remained in that state until they developed congestive heart failure (CHF), distant recurrence (DR), or acute myeloid leukemia (AML

Full access

Cost-Effectiveness Analyses in AML: What Have We Learned, How Should This Impact Patient Care, and What Needs to Be Done in the Future?

Jan Philipp Bewersdorf, Scott F. Huntington, and Amer M. Zeidan

Acute myeloid leukemia (AML) remains the most common form of acute leukemia in adults, with a 5-year survival rate of 30.5% among all patients diagnosed between 2012 and 2018 in the United States. 1 Due to a combination of advances in supportive

Full access

Clinical Trial Accrual at Initial Course of Therapy for Cancer and Its Impact on Survival

Nicholas G. Zaorsky, Ying Zhang, Vonn Walter, Leila T. Tchelebi, Vernon M. Chinchilli, and Niraj J. Gusani

the greatest absolute number of patients in trials: breast, non–small cell lung cancer (NSCLC), pancreas, acute myeloid leukemia, brain, prostate, melanoma, kidney, myeloma, and colorectal 2. Two facility levels: community and academic 3. Four age

Full access

The Multifaceted Nature of Myelodysplastic Syndromes: Clinical, Molecular, and Biological Prognostic Features

Peter L. Greenberg

undergo evolution to or toward acute myeloid leukemia (AML). Pathogenetic mechanisms contributing to clinical phenotypes relate to critical molecular and biologic features. This article focuses on recently reported advances that describe major components

Full access

Financial Implications of Early Hospital Discharge After AML-Like Induction Chemotherapy: A 4-Year Retrospective Analysis

Nathan J. Moore, Megan Othus, Anna B. Halpern, Nicholas P. Howard, Linyi Tang, Kyle E. Bastys, Mary-Elizabeth M. Percival, Paul C. Hendrie, Garrett A. Hartley, Verna L. Welch, Elihu H. Estey, and Roland B. Walter

Background Adults with acute myeloid leukemia (AML) or other high-grade myeloid neoplasms typically remain hospitalized during the several weeks of profound pancytopenia after intensive induction chemotherapy. However, the need for

Full access

Molecular Complete Remission Following Ivosidenib in a Patient With an Acute Undifferentiated Leukemia

Sandipkumar H. Patel, Sumithira Vasu, Ling Guo, Olivia Lemaster, John C. Byrd, and Alison Walker

intravenously on days 1–3) because of the presence of the IDH1 mutation, which is present in 7% to 14% of patients with acute myeloid leukemia (AML). 5 On day 8 of 7+3 treatment, she developed hemoptysis and blurry vision due to bilateral preretinal

Full access

Do All Patients With Polycythemia Vera or Essential Thrombocythemia Need Cytoreduction?

Kamya Sankar and Brady L. Stein

transformation to myelofibrosis (MF) or acute myeloid leukemia (AML). In 2005, the discovery of molecular abnormalities associated with PV and ET were instrumental in understanding the pathophysiologic and clinical manifestations of these disorders. 1 JAK2